Fluroine-18 CSB 321
Alternative Names: [18F]CSB-321Latest Information Update: 09 Jan 2026
At a glance
- Originator Cytosite Bio
- Class Antineoplastics; Fluorine radioisotopes; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Jul 2025 Preclinical trials in Cancer (Diagnosis) in USA (unspecified route)
- 09 Jul 2025 Cytosite Biopharma plans to initiate a phase I trial for Cancer (unresectable, Metastatic disease, Diagnosis) in the US (NCT07057349)